These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34566211)

  • 1. A Review of Tolerance and Safety Profiles of Long-Term Botulinum Neurotoxin Type A in Asian Patients with Hemifacial Spasm and Benign Essential Blepharospasm.
    Lai KKH; Tsang A; Kuk AKT; Ko CKL; Chan E; Ko STC
    Neuroophthalmology; 2021; 45(5):293-300. PubMed ID: 34566211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm.
    Cannon PS; MacKenzie KR; Cook AE; Leatherbarrow B
    Clin Exp Ophthalmol; 2010 Oct; 38(7):688-91. PubMed ID: 20456439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tear meniscus, corneal topographic and aberrometric changes after botulinum toxin-a injection in patients with blepharospasm and hemifacial spasm.
    Bayraktar Bilen N; Bilen Ş; Topçu Yılmaz P; Evren Kemer Ö
    Int Ophthalmol; 2022 Aug; 42(8):2625-2632. PubMed ID: 35355169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
    Ababneh OH; Cetinkaya A; Kulwin DR
    Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.
    Lolekha P; Choolam A; Kulkantrakorn K
    Neurol Sci; 2017 Nov; 38(11):2031-2036. PubMed ID: 28884242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Grey Matter Microstructural Integrity Alterations in Blepharospasm Are Partially Reversed by Botulinum Neurotoxin Therapy.
    Alexandru H; Muthuraman M; Chirumamilla VC; Koirala N; Paktas B; Deuschl G; Zeuner KE; Groppa S
    PLoS One; 2016; 11(12):e0168652. PubMed ID: 27992533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin relieves anxiety and depression in patients with hemifacial spasm and blepharospasm.
    Dong H; Fan S; Luo Y; Peng B
    Neuropsychiatr Dis Treat; 2019; 15():33-36. PubMed ID: 30587995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of Hemorrhagic Side Effects of Botulinum Neurotoxin Treatment in Patients with Blepharospasm and Hemifacial Spasm on Antithrombotic Medication.
    Wenninger FC; Wabbels B
    Toxins (Basel); 2022 Nov; 14(11):. PubMed ID: 36356019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexistent blepharospasm and hemifacial spasm: overlapping pathophysiologic mechanism?
    Tan EK; Chan LL; Koh KK
    J Neurol Neurosurg Psychiatry; 2004 Mar; 75(3):494-6. PubMed ID: 14966174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative absence of psychopathology in benign essential blepharospasm and hemifacial spasm.
    Scheidt CE; Schuller B; Rayki O; Kommerell G; Deuschl G
    Neurology; 1996 Jul; 47(1):43-5. PubMed ID: 8710122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of flexible onabotulinum toxin A treatment in facial dystonia.
    Bladen JC; Feldman I; Favor M; Dizon M; Litwin A; Malhotra R
    Eye (Lond); 2019 Mar; 33(3):349-352. PubMed ID: 30202071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benign essential blepharospasm: risk factors with reference to hemifacial spasm.
    Hall TA; McGwin G; Searcey K; Xie A; Hupp SL; Owsley C; Kline LB
    J Neuroophthalmol; 2005 Dec; 25(4):280-5. PubMed ID: 16340493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of Injection Botulinum Toxin in Blepharospasm.
    Amatya M; Limbu B; Sthapit PR; Gurung HB; Saiju R
    Nepal J Ophthalmol; 2021 Jan; 13(25):40-49. PubMed ID: 33981096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Closely spaced stressful life events precede the onset of benign essential blepharospasm and hemifacial spasm.
    Johnson LN; Lapour RW; Johnson GM; Johnson PJ; Madsen RW; Hackley SA
    J Neuroophthalmol; 2007 Dec; 27(4):275-80. PubMed ID: 18090560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemodenervation for the Treatment of Facial Dystonia: A Report by the American Academy of Ophthalmology.
    Bilyk JR; Yen MT; Bradley EA; Wladis EJ; Mawn LA
    Ophthalmology; 2018 Sep; 125(9):1459-1467. PubMed ID: 29653859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of bangerter occlusion foils on blepharospasm and hemifacial spasm in occlusion-positive and occlusion-negative patients.
    Malhotra R; Then SY; Richards A; Cheek E
    Open Ophthalmol J; 2010 Jan; 4():1-6. PubMed ID: 20148097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm.
    Ho RW; Fang PC; Chao TL; Chien CC; Kuo MT
    Sci Rep; 2018 May; 8(1):8367. PubMed ID: 29849166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A patient-initiated treatment model for blepharospasm and hemifacial spasm: a randomized controlled trial.
    Lawes-Wickwar S; McBain H; Brini S; Hirani SP; Hurt CS; Flood C; Dunlop N; Solly D; Crampton B; Newman SP; Ezra DG
    BMC Neurol; 2022 Mar; 22(1):99. PubMed ID: 35300599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
    Bihari K
    Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported outcomes following a break in ophthalmic botulinum toxin therapy during the COVID-19 pandemic.
    Jamison A; Favor M; Malhotra R
    Can J Ophthalmol; 2024 Feb; 59(1):e41-e45. PubMed ID: 36372133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.